Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://moehs.com/2grants-from-centro-para-el-desarrollo-tecnologico-y-la-innovacion/

PRESS RELEASE
18 Jun 2024

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-partners-with-pfizer-to-launch-abrocitinib-in-india-to-treat-atopic-dermatitis/articleshow/107296402.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

ECONOMIC TIMES
31 Jan 2024

https://www.businesswire.com/news/home/20230210005281/en/FDA-Approves-Pfizers-Supplemental-New-Drug-Application-for-CIBINQO%C2%AE-abrocitinib

BUSINESSWIRE
10 Feb 2023
2022 drug approvals: Biopharma delivered 37 new drugs
2022 drug approvals: Biopharma delivered 37 new drugs

03 Jan 2023

// Kevin Dunleavy FIERCE PHARMA

https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come

Kevin Dunleavy FIERCE PHARMA
03 Jan 2023

https://www.biopharmadive.com/news/ema-recommends-jak-inhibitors-restrictions/636343/

BIOPHARMADIVE
12 Nov 2022
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC

01 Nov 2022

// Catherine Eckford EUROPEANPHARMACEUTICALREVIEW

https://www.europeanpharmaceuticalreview.com/news/175849/jak-inhibitors-unsafe-for-cardiovascular-cancer-risk-prac/

Catherine Eckford EUROPEANPHARMACEUTICALREVIEW
01 Nov 2022